Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep;32(9):1018-1029.
doi: 10.1038/s41417-025-00943-3. Epub 2025 Jul 24.

Long non-coding RNA PRSS23-AS1 as ceRNA promotes breast cancer progression by regulating EMT via miR-3176 /YBX1 axis

Yun Huang #  1 , Mudan Feng #  2 , Yiwei Jiang #  1   3 , Maihuan Wang  4 , Mingkun Wang  5 , Zhen Cao  6   7   8
Affiliations

Long non-coding RNA PRSS23-AS1 as ceRNA promotes breast cancer progression by regulating EMT via miR-3176 /YBX1 axis

Yun Huang et al. Cancer Gene Ther. 2025 Sep.

Abstract

Breast cancer (BC) remains a leading cause of cancer-related mortality, largely due to its aggressive proliferation and metastatic potential. Long non-coding RNAs (lncRNAs) have emerged as key regulators in tumor development and progression. This study explored the functional role and mechanism of Lnc-PRSS23-AS1 in BC. We assessed Lnc-PRSS23-AS1 expression and localization using fluorescence in situ hybridization, qRT-PCR, and Western blotting in BC tissues and cell lines. Binding interactions between Lnc-PRSS23-AS1, miR-3176, and Y-box binding protein 1 (YBX1) were validated through dual-luciferase reporter assays, RNA pulldown, and RNA immunoprecipitation. Lnc-PRSS23-AS1 was significantly upregulated in BC and predominantly localized in the cytoplasm. Silencing Lnc-PRSS23-AS1 or overexpressing miR-3176 suppressed BC cell proliferation, migration, and invasion in vitro and in vivo. Conversely, miR-3176 inhibition or YBX1 overexpression reversed these effects. Mechanistically, Lnc-PRSS23-AS1 promoted YBX1 protein expression by acting as a molecular sponge for miR-3176. These findings highlight the Lnc-PRSS23-AS1/miR-3176/YBX1 axis as a driver of BC progression and suggest Lnc-PRSS23-AS1 as a potential therapeutic target for breast cancer treatment.

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors declare that they have no competing interests. Ethics approval and consent to participate: The present study received approval from the Sixth Medical Center of the PLA General Hospital (Beijing, China) and adhered to the Declaration of Helsinki. All procedures involving animal care and use were approved by the Experimental Animal Ethics Committee of the Beijing Geneline Bioscience Biotechnology Company and followed the National Policy on the Use of Laboratory Animals. Consent for publication: All authors agreed to this publication.

References

    1. Harbeck N, Gnant M. Breast cancer. Lancet. 2017;389:1134–1150. - PubMed
    1. Xu H, Xu B. Breast cancer: epidemiology, risk factors and screening. Chin J Cancer Res. 2023;35:565–583. - PubMed - PMC
    1. Burstein HJ, Curigliano G, Thürlimann B, Weber WP, Poortmans P, Regan MM, et al. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann Oncol. 2021;32:1216–1235. - PubMed
    1. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17–48. - PubMed
    1. Bi Z, Wang Y. Advances in regional nodal management of early-stage breast cancer. Chin J Cancer Res. 2024;36:215–225. - PubMed - PMC

MeSH terms

LinkOut - more resources